clinical trial · NCT03911102
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
Revance Therapeutics, Inc.·phase2·completed·n = 63
Lateral Canthal LinesDaxibotulinumtoxinA for injection
brief summary
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
started
Mar 11, 2019
primary completion
Apr 23, 2020
completion
Apr 23, 2020
last updated
Jun 27, 2023
official title
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol